[Oligonucleotide-based therapy as a potential new pharmacotherapy].
Recent progress in molecular biology has provided new techniques to inhibit target gene expression. Especially, the application of DNA technology such as antisense strategy to regulate the transcription of disease-related genes in vivo has important therapeutic potential. Recently, transfection of cis-element double-stranded (ds) oligodeoxynucleotides (ODN) (= decoy) as a powerful tool in a new class of anti-gene strategies for gene therapy and the study of transcriptional regulation has been reported. Transfection of ds ODN corresponding to cis sequence will result in the attenuation of authentic cis-trans interaction, leading to the removal of trans-factors from the endogenous cis-elements with subsequent modulation of gene expression. This "decoy" strategy is not only a novel strategy for gene therapy as an anti-gene strategy, but also a powerful tool for the study of endogenous gene regulation in vivo as well as in vitro. In this article, we reviewed 1) the mechanisms, and 2) potential applications of decoy strategy.
Morishita
R
R
Division of Gene Therapy Science, Osaka University Medical School, Suita-shi, Japan.
D015316:Genetic Therapy; D006083:Graft Occlusion, Vascular / Q000628:therapy; D006801:Humans; D009203:Myocardial Infarction / Q000628:therapy; D009369:Neoplasms / Q000628:therapy; D009393:Nephritis / Q000628:therapy; D020319:Oligodeoxyribonucleotides, Antisense / Q000235:genetics / Q000494:pharmacology / Q000627:therapeutic use*; D014157:Transcription Factors / Q000378:metabolism; D014162:Transfection
D020319:Oligodeoxyribonucleotides, Antisense; D014157:Transcription Factors